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Introduction
It is a standard practice to recommend radiotherapy
(RT) to residual breast after breast conserving surgery
(BCS). Recurrence rate at the remaining breast near to
the tumour after BCS ranges between 43-9% without
radiotherapy [1-5]. The difference depends on structure
of evaluated subgroups and different term of the fol-
low- up.
Now, data from seven randomized trials have shown
a substantial improvement in local tumour control in
irradiated patients after BCS compared to non-irradiated
on average from 27% to 7% at 10 years [6-7]. Moreover,
there is a well-established practice in most European
countries and in US to give an additional dose as a "boost"
to the tumour area. The rationale for such increase of
NOWOTWORY Journal of Oncology • 2002 • volume 52
Number 6 • 497–501
Indications for boost irradiation after quadrantectomy for early breast cancer
Lena Marinova, Tatiana Hadjieva
I n t r o d u c t i o n.  Controversies still exist on boost irradiation after quadrantectomy for early breast cancer.
M a t e r i a l  a n d  m e t h o d s.  A retrospective study on 341 pTNM I-II staged (<3 cm) patients aimed to evaluate boost
irradiation effect mainly upon local tumour control, measured by Recurrence Free Survival - (RFS) and consequently to
Disease Free Survival (DFS). Whole breast, scar and chest wall were irradiated by 50 Gy telecobalttherapy in all patients and
224 of them were chosen to receive additional 10 Gy to the tumour bed.
R e s u l t s  a n d  c o n c l u s i o n.  No significant difference was registered in 10 years RFS (96%) in 224 patients receiving 10
Gy boost irradiation, compared to 95% RFS of the 117 patients irradiated with 50 Gy to the whole breast. DFS was 89% at
10th year and did not differ in both groups. The local relapse rate at 10th year was among the lowest figures reported – 3.4%
for boost group and 3.6% for no-boost group. Proportional hazard Cox model reveal a high-risk group for local recurrence that
might benefit from boost irradiation (tumour size 2.1-3 cm; G3, negatives steroid receptors). In our practice, patients develo-
ping such characteristics have indications for boost irradiation.
Radioterapia u chorych z wczesnym rakiem sutka po kwadrantektomii 
– wskazania do podwy˝szenia dawki na wydzielone pole („boost”)
W s t ´ p.  Istniejà kontrowersje dotyczàce stosowania podwy˝szonej dawki na wydzielone pole („boost") u chorych po kwadran-
tektomii, wykonanej we wczesnym raku sutka.
M a t e r i a ∏  i m e t o d y.  Przeprowadzono retrospektywnà analiz´ 341 chorych z rakiem sutka w stadium pTNM I/II (guz po-
ni˝ej 3 cm Êrednicy) po kwadrantektomii pod kàtem oceny stosowania podwy˝szonej dawki na wydzielone pole („boost”)
w celu zapewnienia kontroli miejscowej, mierzonej jako czas prze˝ycia bez wznowy (Recurrence Free Survival, RFS)
i w efekcie, czas prze˝ycia bez choroby (Disease Free Survival, DFS). Podawano dawk´ 50 Gy (technikà teleradioterapii ko-
baltowej) na ca∏à pierÊ, blizn´ pooperacyjnà i Êcian´ klatki piersiowej, a u 224 chorych dodatkowo "boost" 10 Gy, skierowa-
ny na lo˝´ po guzie.
W y n i k i  i w n i o s k i.  W ciàgu 10 lat obserwacji nie stwierdzono statystycznie znamiennej ró˝nicy w zakresie odsetka RFS:
96% w grupie 224 chorych, które otrzyma∏y "boost" i 95% w grupie 117 chorych, które nie otrzyma∏y „boostu”. Odsetek DFS
by∏ w 10-tym roku obserwacji taki sam w obu grupach – tj. 89%. Odsetek wznów miejscowych po 10 latach nale˝a∏ do najni˝-
szych opisywanych w literaturze – 3,4% w grupie, która otrzyma∏a „boost” i 3,6% chorych w grupie, która nie otrzyma∏a „bo-
ostu”. Analiza wieloczynnikowa metodà Coxa pozwoli∏a wy∏oniç grup´ chorych o podwy˝szonym ryzyku wznowy miejscowej,
które mog∏yby odnieÊç wyraênà korzyÊç z naÊwietlania, z zastosowaniem podwy˝szonej dawki na wydzielone pole. Sà to
chore, u których rozmiary guza osiàgajà 2,1-3 cm, nowotwór zaÊ wykazuje cech´ G3 i nie posiada receptorów steroidowych.
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the dose is based on a theory that a lower recurrence
rate will be achieved without severe risk of local radiation
complications [8-9].
The need for dose boost is questioned, if operative
margins are clear from tumour cells after type of surgery
as quandartectomy or expanded sectoral resection [10-13].
Therefore, a definition of a risk group that might benefit
from high dose irradiation is very important.
Our study aimed to analyse the benefit of 10 Gy
boost given by telecobalttherapy after quadrantectomy
in early (>3 cm) breast cancer.
Material and methods
In the period 1987-1997, 345 patients with pTNM Stage I and
Stage II (>3 cm) breast cancer were treated at the Department
of Radiotherapy, University Hospital "Queen Giovanna", Sofia.
The median follow-up was 6.5 years, ranging from 1.5 to 11.5
years. All patients underwent quadrantectomy with axillary dis-
section as BCS. Adjuvant chemotherapy and hormonal therapy
were added if there were indications for it.
One month after the operation patients were subjected
to 60Co external beam RT. The clinical target volume (CTV-1)
in pN0 patients included the breast with the operative scar and
the underlying chest wall; they received a total dose (TD) of
50 Gy. Patients with pNx (below dissected 7 negative axillary
lymph nodes) and pN1 were irradiated with the extra CTV vol-
ume which included the regional nodal areas (axillary, ipsilateral
mammary, supraclavicular) up to a TD of 50 Gy (CTV-2).
245 chosen at the descretion of a physician patients (66%)
received 10 Gy extra beam boost to the tumor bed. Clinical
characteristics of boost and non-boost group are shown on
Table I. No significant differences were calculated between
both arms.
Recurrence-free survival was evaluated as a primary clini-
cal end-point. We have chosen a Disease-Free Survival to be
a secondary end-point as a common criterion for local and dis-
tant failures. Survival analysis was calculated by Kaplan Mayer
method. The level of significance was set as p<0.05. All p values
were two-tailed. A benefit from boost radiation according to
some prognostic factors was tested by Cox regression model.
Following variables were studied in both groups: pT, G, steroid
receptors, volume of axillary dissection (under or over 7 dis-
sected lymph nodes). Statistical analysis was computed by stan-
dard PC package from Statistica [14]
Results
B o o s t  i r r a d i a t i o n  a n d  l o c a l  t u m o u r
c o n t r o l .  Re c u r r e n c e - f r e e  s u r v i v a l
Detailed characteristics and treatment of the patients
with local recurrences are shown on Table II. Twelve cases
(3.5%) with local recurrence were registered in both
groups. All recurrences were developed 1-5.5 years after
RT and 96% of patients a remained local tumour free.
There were no relapses registered in the regional lymph
nodes areas. Nine of the local relapses are marginal. They
were located less then 3 cm from the operative scar, that
is very near to the primary tumor bed. Three skin relaps-
es were registered into the radiation field. High-risk his-
tological characteristics were presented in both groups
with relapses. Ten out of twelve patients with local relapse
are alive. Radical mastectomy alone or combined with
adjuvant chemotherapy was carried out as a salvage treat-
ment. Two of the recurred patients developed pulmonary
and hepatic distant metastases and later succumbed.
Eight recurrences (3.6%) were registered In the
boost group after delivering an extra boost dose of 10
Gy to 50 Gy at the whole breast. The remaining four
relapses were observed in non – boost group (3.4%).
Obviously, the boost irradiation after quadrantectomy
does not show higher local tumour control.
Figure 1 presents comparative Recurrence Free
Survival (RFS) in boost and no- boost groups. Ten years
RFS is between 96-95% with no difference between two
curves (log rank p=0.56).
Figure 2 shows a comparative RFS in additionally
selected group of pT2 patients with tumour size between
2.1 and 3 cm. No significant difference (p=0.39) was
registered in the first group that received a higher dose
given as a boost; nevertheless 91.6% did not recurred in
comparison with 81% in the second group.
Further analysis was made in patients selection
having two risk parameters: tumour size 2.1-3cm and low
tumour differentiation – G3. The numbers of observations
became smaller and smaller (18 in the boost and 19 in the
no-boost group) and no difference in RFS were detected
Figure 3 (p=0.8). However, it seems that parameter G3
further declines RFS in both groups (86% and 82%).
Table II. Clinical, pathological and treatment characteristics of patients with local relapse
Boost Age Histology pT pN G LTC Ca Tumour Micro Tumour Vessel Distant Hormone Chemo Outcome
(cm) (years) in situ necrosis -calcificates metaplasia invasion metastases therapy -therapy
yes 38 Gelatinous 2 N1 G2 2.8 yes no yes no no no yes yes alive
yes 54 Invas. ductal 1 N0 G2 1.5 no yes no no yes no no no alive
yes 55 Invas. ductal 3 N0 G3 1.4 no no no yes no yes yes no dead
yes 57 Invas. lobular 1 N0 Gx 1.5 no no no no no no yes yes alive
yes 44 Invas. ductal. 2 N1 G3 1.0 no no yes no no no yes yes alive
yes 54 Invas. ductal. 3 N1 G3 1.5 no no yes no no no yes yes alive
yes 54 Invas. ductal. 3 N1 G3 1.5 no no yes no no no no yes alive
yes 35 Invas. ductal. 1 N1 Gx 5.5 no no no no no no yes yes alive
no 47 Gelatinous 2 N1 G1 2.9 no no no no no no yes yes alive
no 51 Invas. ductal 3 N1 Gx 5.0 no no no no no yes yes yes dead
no 40 Invas. lobular 1 N0 Gx 2.0 no no no no no no yes no alive
no 39 Invas. ductal 2 N0 Gx 1.0 no no no no no no no no alive
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Figure 4. Disease Free Survival of patients with early breast cancer after quadrantectomy and
radiotherapy for boost and no-boost group
Figure 1. Recurrence Free Survival of patients with early breast cancer after quadrantectomy and
radiotherapy for boost and no-boost group
Figure 2. Recurrence Free Survival in boost and no-boost group, with tumour size between 2.1 and 3.0 cm
(pT2)
Figure 3. Recurrence Free Survival in pT2 (2.1-3.0 cm) and G3 boost and no-boost group
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D i s e a s e  f r e e  s u r v i v a l  ( D F S )
Two of the recurred patients developed pulmonary and
hepatic distant metastases and later succumbed. They
belong to each of the compared groups. DFS is presented
on Figure 4. Again, no difference in DFS was detected in
two investigated patients groups reaching 89% at 10th years.
Discussion
Our study include a substantial number of patients: 117
cases whose remaining breast was irradiated up to TD
50 Gy and 224 patients with additional 10 Gy boost irra-
diation. Both groups were balanced according to patient,
tumour and treatment characteristics (Table I).
Table I. Patients, tumour and treatment characteristics in both groups
Parameters Boost group No- boost group P
N % N %
All 224 65.7 117 34.3
Age (years)
>30 4 18 1 1.0 0.82
31-40 23 10.3 25 21.4 0.19
41-50 81 36.0 34 29.0 0.26
51-60 65 29.0 32 27.4 0.84
<60 51 22.8 25 21.4 0.92
Histology
Invasive ductal 174 77.7 94 80.3 0.7
Invasive lobular 27 12.0 14 12.0 1.0
Others 23 10.3 9 7.7 0.8
High risk parameters
pT2 /(2.1-3 cm) 39 17.5 31 26.5 0.36
G3 35 15.6 15 12.8 0.78
Microcalcificates 11 5.0 4 3.4 0.93
Comedo structures 7 3.0 4 3.4 0.93
Lymph vessel invasion 2 1.0 2 1.7 0.95
Venous vessel invasion 5 2.2 1 1.0 0.91
Tumour necrosis 6 2.7 0 0 0.39
Tumour metaplasia 3 1.3 0 0
EIDC in situ ductale 2 1 1 1
EIDC in situ lobulare 4 1.8 1 1
Steroid receptors negative 56 25.0 18 15.4 0.38
Hormonal therapy 160 72.0 81 70.0 0.74
Adjuvant chemotherapy 68 30.0 23 20.0 0.35
The 10-survival analysis demonstrates significant
difference neither in RFS nor in DFS between boost and
no-boost arms. Our 10-years long-term results reveal the
good level of Bulgarian oncological practice in early
breast cancer ranking them among the best survival
results (96-95% RFS and 89% DFS) [5, 6].
The numbers of observation event in our study –
12 cases with local relapses after radiotherapy – were
too small to prove any difference, if it exists. Only 4 out
of 117 patients, receiving 50 Gy developed local
recurrences. Similarly, 8 out of 224 patients showed local
relapse despite of 60 Gy administered by
telecobalttherapy. Zissiadis and al. [15] reported no
influence on LTC at 5 years in 78% of his patients treated
by quadrantectomy and additional boost irradiation.
Similar conclusion was made in NSABP-06 trial [16]. Only
8% of local relapses were registered at 5 years without
boost irradiation.
Later, two large randomised trials investigated the
benefit after boost irradiation. The results from Lion trial,
France, were based on 1024 patients treated by lumpecto-
my with negative margins and 50 Gy tangential radiation
to the whole breast, randomised to either 10 Gy boost or
no further RT. The relative risk for local recurrence at
the 5th year was higher in the no-boost arm (4.5% compa-
re to 3.6%) (p <0.044) and the authors advocate the bene-
fit of boost irradiation in case of negative margins [17].
The EORTC boost trial increased the cohort and
includes 5318 patients to prove or disprove the benefit
from 16 Gy boost irradiation after lumpectomy with nega-
tive margins [18, 19]. The absolute benefit was 2.5% at the
5th years with a significant decrease of local recurrences
from 6.8% in the no-boost arm compared to 4.3% in the
boost arm (p<0.0001). In younger patients boost RT sho-
wed higher advantage for LTC than in the patients over
50 years of age. EORTC trial concludes that boost irradia-
tion is essential in case of unclear or positive margins
after lumpectomy.
The EORTC boost trial increased the cohort and in-
cludes 5318 patients to prove or disprove the benefit from
16 Gy boost irradiation after lumpectomy with negative
margins [18, 19]. The absolute benefit was 2.5% at the 5th
years with a significant decrease of local recurrences from
6.8% in the no-boost arm compared to 4.3% in the boost
arm (p<0.0001). Boost RT shows higher advantage in
younger patients than in the patients over 50 years of age.
EORTC trial concludes that boost irradiation is essential
in case of unclear or positive margins after lumpectomy.
We could not investigate the relation between
surgical margins and boost irradiation. A clear evidence
of margins status could not be found in the operative
protocols of all patients. In a number of them, the
information was lacking, because evaluating procedure
of surgical margins still is not a routine practice in some
Bulgarian hospitals. In some cases, the precise infor-
mation about volume of exised breast was also missing.
So, the margin status of our patients could be addressed
as unknown, as cited in many publications
Trying to overcome the disadvantage of the low
numbers of events, we performed a regression analysis
by proportional multivariate hazard Cox model. We
analyzed the influence of several prognostic parameters
(PP) on RFS in each group: tumour size 2.1-3 cm versus
smaller size, degree of differentiation (G3 versus G1 plus
G2), volume of axillary clearance (under and over seven
negative lymph nodes) and tumour steroid receptors
status (positive versus negative) (Table III).
PP as bigger tumour size (p=0.0125), G3 (0.0001),
negative steroid receptors (0.0068) have a negative
influence on RFS of non-boost arm.
The boost irradiation overcome the above registered
negative influence of bigger pT, G3 and negative
hormonal receptors on local RFS (Table III).
Proportional Cox regression analysis did not reveal
influence of other parameters as negative prognostic
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factors for local recurrence in both groups:
microcalcifications, tumour necrosis, vessel invasion,
tumour metaplasia, extensive intraductal component
(EIDC), comedo structures
Our study does not pretend for final conclusive
results. The figures of 3.4-3.6% local recurrence rate in
both evaluated groups are among the lowest data cited in
the literature. It might be a result of wider surgery with
negative margins. Simultaneously, we achieved good
cosmetic results in boost group that has been reported
elsewhere [20].
The long term survival with equivalent evaluation
of cosmetic results will reveal further information
concerning ultimate local control rate as well as ultimate
survival in relation to higher dose postoperative RT in
BCS [21].
Conclusions
1. There was no significant difference registered in 10
years RFS (96%) in patients receiving 10 Gy boost
irradiation, compared to 95% RFS of the patients
irradiated by 50 Gy to the whole breast.
2. DFS was 89% at 10th year in the cohort of 341 patients
after BCS in early breast cancer (pT<3 cm)
3. The relapse rate at 10th year was among the lowest
figures reported – 3.4% for boost group and 3.6% for
no-boost group.
4. Proportional hazard Cox model reveal a high-risk
group for local recurrence that might benefited from
boost irradiation after quadrantectomy with unknown
surgical margin (tumour size 2.1-3 cm, G3, negative
steroid receptors).
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Table III. Influence of boost irradiation on Recurrence 
– Free Survival related to four tumour parameters. 
The analysis was performed by Proportional Hazard Cox model
Parameter Chi2 df p value
RFS in patients without boost Chi2 55.5 p=0.00001
irradiation df=4
Variables β
Tumour size (2.1-3 cm) -0.23 p= 0.01
Volume of axillary dissection -0.02 p=0.06
Degree of differentiation (G) -0.83 p=0.00
Positive steroid receptors -0.15 p=0.006
RFS in patients with boost irradiation Chi2 2.7 p=0.59
df=4
Variables β
Tumour size (2.1-3 cm) -0.05 p=0.70
Volume of axillary dissection -0.01 p=0.23
Degree of differentiation (G) -0.21 p=0.29
Positive steroid receptors -0.02 p=0.73
